Here are the top 5 biosimilar articles for the week of June 21, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of June 21, 2021.
Number 5: The Supreme Court ruled that plaintiffs had no standing to challenge the constitutionality of the Affordable Care Act, saving the Biologics Price Competition and Innovation Act (BPCIA), which is the regulatory pathway for biosimilar approvals.
Number 4: Sophia Z. Humphreys, PharmD, MHA, explained how biosimilar utilization management can enable health care institutions to put COVID-19–related financial wreckage behind them.
Number 3: Real-world studies demonstrated comparable safety for trastuzumab biosimilars (Kanjinti and Zedora) vs the originator (Herceptin) and were presented at the ASCO 2021 Annual Meeting.
Number 2: Positive findings were reported for use of a bevacizumab biosimilar (Byvasda) in combination with sintilimab as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC).
Number 1: The “winner-takes-all” tender process for biosimilar procurement in the European Union runs the risk of driving competitors out of the market, authors of a new survey contended.
To read all of these articles and more, visit centerforbiosimilars.com.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.